|
1
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:pp. 10869–10874. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prat A, Cheang MC, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel
Members: Tailoring therapies-improving the management of early
breast cancer: St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2015. Ann Oncol.
25:1533–1546. 2015. View Article : Google Scholar
|
|
6
|
Rashid OM and Takabe K: The evolution of
the role of surgery in the management of breast cancer lung
metastasis. J Thorac Dis. 4:420–424. 2012.PubMed/NCBI
|
|
7
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Society TJBC, . General rules for clinical
and pathological recording of breast cancer. 2012.
|
|
9
|
Ohara M, Akimoto E, Noma M, Matsuura K,
Doi M, Kagawa N and Itamoto T: Prognostic impact of progesterone
receptor status combined with body mass index in breast cancer
patients treated with adjuvant aromatase inhibitor. Oncol Lett.
10:3286–3292. 2015.PubMed/NCBI
|
|
10
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Breast Cancer Version 2.2015. J Natl Compr Canc
Netw. 13:448–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brown LM, Chen BE, Pfeiffer RM, Schairer
C, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M,
et al: Risk of second non-hematological malignancies among 376,825
breast cancer survivors. Breast Cancer Res Treat. 106:439–451.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kirova YM, De Rycke Y, Gambotti L, Pierga
JY, Asselain B and Fourquet A; Institut Curie Breast Cancer Study
Group, : Second malignancies after breast cancer: The impact of
different treatment modalities. Br J Cancer. 98:870–874. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shilkrut M, Belkacemi Y and Kuten A;
Association of Radiotherapy and Oncology of the Mediterranean arEa
(AROME), : Secondary malignancies in survivors of breast cancer:
How to overcome the risk. Crit Rev Oncol Hematol. 84 Suppl
1:e86–e89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vidal-Millan S, Zeichner-Gancz I,
Flores-Estrada D, Vela-Rodríguez BE, Vazquez-López MI, Robles-Vidal
CD, Ramirez-Ugalde MT and Chávez-MacGregor M: A descriptive study
of second primary malignancies associated to breast cancer in a
mexican Hispanic population. Med Oncol. 22:17–22. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jensen JD, Knoop A, Ewertz M and Laenkholm
AV: ER, HER2, and TOP2A expression in primary tumor, synchronous
axillary nodes and asynchronous metastases in breast cancer. Breast
Cancer Res Treat. 132:511–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanaka F, Li M, Hanaoka N, Bando T, Fukuse
T, Hasegawa S and Wada H: Surgery for pulmonary nodules in breast
cancer patients. Ann Thorac Surg. 79:1711–1715. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rena O, Papalia E, Ruffini E, Filosso PL,
Oliaro A, Maggi G and Casadio C: The role of surgery in the
management of solitary pulmonary nodule in breast cancer patients.
Eur J Surg Oncol. 33:546–550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan J, Chen D, Du H, Shen C and Che G:
Prognostic factors for resection of isolated pulmonary metastases
in breast cancer patients: A systematic review and meta-analysis. J
Thorac Dis. 7:1441–1451. 2015.PubMed/NCBI
|
|
20
|
Dieci MV, Barbieri E, Piacentini F,
Ficarra G, Bettelli S, Dominici M, Conte PF and Guarneri V:
Discordance in receptor status between primary and recurrent breast
cancer has a prognostic impact: A single-institution analysis. Ann
Oncol. 24:101–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amir E, Miller N, Geddie W, Freedman O,
Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G,
Laupacis A, et al: Prospective study evaluating the impact of
tissue confirmation of metastatic disease in patients with breast
cancer. J Clin Oncol. 30:587–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thompson AM, Jordan LB, Quinlan P,
Anderson E, Skene A, Dewar JA and Purdie CA; Breast Recurrence in
Tissues Study Group, : Prospective comparison of switches in
biomarker status between primary and recurrent breast cancer: The
breast recurrence in tissues study (BRITS). Breast Cancer Res.
12:R922010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Welter S, Jacobs J, Krbek T, Tötsch M and
Stamatis G: Pulmonary metastases of breast cancer. When is
resection indicated? Eur J Cardiothorac Surg. 34:1228–1234. 2008.
View Article : Google Scholar : PubMed/NCBI
|
